Rocket Pharmaceuticals, Inc.RCKTNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-20.14%
↓ 176% below average
Average (39q)
26.49%
Historical baseline
Range
High:778.13%
Low:-76.79%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -20.14% |
| Q2 2025 | 18.69% |
| Q1 2025 | -3.79% |
| Q4 2024 | -11.72% |
| Q3 2024 | -5.53% |
| Q2 2024 | 2.36% |
| Q1 2024 | 4.83% |
| Q4 2023 | -10.89% |
| Q3 2023 | -8.83% |
| Q2 2023 | 10.81% |
| Q1 2023 | -7.33% |
| Q4 2022 | 15.34% |
| Q3 2022 | 4.90% |
| Q2 2022 | 34.30% |
| Q1 2022 | -4.25% |
| Q4 2021 | -18.83% |
| Q3 2021 | 61.52% |
| Q2 2021 | -13.35% |
| Q1 2021 | -44.53% |
| Q4 2020 | 135.66% |
| Q3 2020 | 29.44% |
| Q2 2020 | -1.33% |
| Q1 2020 | 15.61% |
| Q4 2019 | -1.09% |
| Q3 2019 | 6.00% |
| Q2 2019 | -7.58% |
| Q1 2019 | -36.08% |
| Q4 2018 | 81.25% |
| Q3 2018 | 21.29% |
| Q2 2018 | 87.57% |
| Q1 2018 | 778.13% |
| Q4 2017 | -76.79% |
| Q3 2017 | -22.24% |
| Q2 2017 | -48.94% |
| Q1 2017 | -25.24% |
| Q4 2016 | 12.85% |
| Q3 2016 | 30.12% |
| Q2 2016 | -15.10% |
| Q1 2016 | 28.65% |
| Q4 2015 | 63.87% |